zstk474 profile

ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	11647372
CHEMBL ID	586702
CHEBI ID	90545
SCHEMBL ID	373282
MeSH ID	M0497877

Synonym
HY-50847
2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine
4,4'-(6-(2-(difluoromethyl)-1h-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine
zstk-474
zstk474 ,
CHEMBL586702 ,
chebi:90545 ,
AKOS005145982
FT-0651454
bdbm50315213
4,4''-(6-(2-(difluoromethyl)-1h-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine
2-(difluoromethyl)-1-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-1h-benzimidazole
TCMDC-137004 ,
zs4 ,
EX-3329
zstk 474
475110-96-4
2-(difluoromethyl)-1-(4,6-dimorpholino-1,3,5-triazin-2-yl)-1h-benzo[d]imidazole;zstk474
A15585
HMS3265I19
HMS3265J19
HMS3265J20
HMS3265I20
HMS2043A02
BCPP000001
NCGC00346484-01
2-(2-difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine
k0068gk39a ,
unii-k0068gk39a
CS-0083
BRD-K63068307-001-01-4
2-(difluoromethyl)-1-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]benzimidazole
gtpl7965
2WXL ,
SCHEMBL373282
S1072
ethyl3-bromothiophene-2-carboxylate
1-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-1h-benzimidazole
2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1h-benzimidazole
AC-28418
J-513955
DTXSID30197179
HMS3654I15
mfcd08705334
NCGC00346484-08
SW220182-1
DB12904
F15198
EX-A2207
Q27089303
AS-16245
BCP01867
4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine
SB17043
CCG-264806
nsc-800993
nsc800993
nsc-764516
nsc764516
hgvnlrpzowwdkd-uhfffaoysa-n

Excerpt	Reference	Relevance
"ZSTK474 is a new PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs. "	( Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. Fukui, Y; Gouda, H; Hirono, S; Koshimizu, I; Matsuno, T; Yaguchi, S; Yamazaki, K; Yamori, T; Yoshimi, H, 2006)	2.09
"ZSTK474 (4a) is a potent, pan-PI3K inhibitor currently under clinical evaluation for the treatment of cancer."	( Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. Jennings, IG; Miller, MS; Pinson, JA; Thompson, PE; Zheng, Z, 2013)	1.11
"ZSTK474 is a potent phosphoinositide 3-kinase (PI3K) inhibitor that reduces cell proliferation via G"	( Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells. Callaghan, R; Muthiah, D, 2017)	2.17
"ZSTK474 is a specific PI3K inhibitor developed for solid tumor therapy."	( In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells. Duan, HQ; Guo, W; Jin, M; Kong, D; Ma, SN; Qiu, Y; Wang, R; Zhao, W; Zhou, Q, 2013)	1.34
"ZSTK474 is a specific phosphatidylinositol 3-kinase (PI3K) inhibitor that we identified."	( In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells. Chen, X; Chen, Y; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhao, W; Zhong, Y; Zhou, Q, 2016)	1.43
"ZSTK474 is a highly promising antitumor agent targeting PI3K."	( Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Kong, D; Yaguchi, S; Yamori, T, 2009)	1.48
"ZSTK474 is a novel orally applicable phosphoinositide 3-kinase-specific inhibitor that strongly inhibits cancer cell proliferation. "	( Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo. Anzai, K; Dan, S; Enami, J; Okamura, M; Okayasu, R; Sekine-Suzuki, E; Ueno, M; Yaguchi, S; Yamori, T; Yoshimi, H, 2011)	2.03

Excerpt	Reference	Relevance
"ZSTK474 can inhibit the pathway of PI3K/AKT, ZSTK474 alone or in combination with Homoharringtonine shows potential antileukemia activity on U937 cells."	( [The Antileukemia Activity of ZSTK474 on U937 Cells]. Chen, T; Kong, DX; Qiu, YL; Zhou, QX, 2021)	2.35

Excerpt	Reference	Relevance
"Treatment by ZSTK474 resulted in cell cycle arrest in G1 phase, which might be associated with upregulation of p27, and downregulation of cyclin D1."	( In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells. Chen, X; Chen, Y; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhao, W; Zhong, Y; Zhou, Q, 2016)	1.07
"Treatment with ZSTK474 after X-irradiation also inhibited phosphorylation, and remarkably inhibited xenograft tumor growth."	( Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo. Anzai, K; Dan, S; Enami, J; Okamura, M; Okayasu, R; Sekine-Suzuki, E; Ueno, M; Yaguchi, S; Yamori, T; Yoshimi, H, 2011)	0.93

Excerpt	Reference	Relevance
" In conclusion, ZSTK474 showed potent antiproliferative effect on HL60 and HL60/ADR cells; combination with cytarabine or vincristine resulted in synergistic effect."	( Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. Chen, Y; Gong, M; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhang, L; Zhang, Z; Zhong, Y; Zhou, Q, 2017)	1.1

Excerpt	Reference	Relevance
" Compound 14 showed a 95% and 67% inhibition of tumor ERK1/2 and Akt phosphorylation, respectively, at 2 h postadministration by Western blot analysis, confirming the bioavailability and efficacy of this bifunctional inhibitor strategy toward combined MEK1/PI3K inhibition."	( Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K). Blanks, AE; Galbán, S; Hong, H; Lombardi, RL; Nino, CA; Ross, BD; Van Dort, ME; Wang, H, 2016)	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" This compound was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1(-/-) mice, and at a dose of 50 mg/kg given by ip injection at a qd × 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls."	( Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Baguley, BC; Buchanan, CM; Denny, WA; Flanagan, JU; Frederick, R; Gamage, SA; Jamieson, SM; Kendall, JD; Kestell, P; Kolekar, S; Lee, WJ; Lill, CL; Marshall, ES; Rewcastle, GW; Shepherd, PR; Singh, R, 2011)	0.56

Role	Description
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	An inhibitor of phosphatidylinositol 3-kinase, EC 2.7.1.137, a family of related enzymes capable of phosphorylating the 3 position hydroxy group of the inositol ring of a phosphatidylinositol.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
morpholines	Any compound containing morpholine as part of its structure.
benzimidazoles	An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
triamino-1,3,5-triazine
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	1.8655	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	0.5868	0.0052	9.4661	32.9993	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	7.5637	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	1.1661	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
polyprotein	Zika virus	Potency	1.8655	0.0030	8.7949	48.0869	AID1347053
Interferon beta	Homo sapiens (human)	Potency	0.8634	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Chain A, PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM	Mus musculus (house mouse)	IC50 (µMol)	0.0046	0.0046	0.0673	0.1300	AID977608
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	GI50	0.0280	0.0280	0.0280	0.0280	AID1912695
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	IC50 (µMol)	0.0105	0.0001	0.3371	7.3000	AID1177100; AID1189522; AID1321994; AID1491586; AID1578120; AID1824111; AID1913108; AID496762; AID626771; AID648509; AID719910; AID725588; AID727784
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0281	1.4295	6.0390	AID1177094; AID1321991
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0003	0.6450	5.3000	AID1177095; AID1321992
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.0049	0.0000	0.6832	10.0000	AID1321994; AID1424604; AID1491583; AID1491586
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	GI50	0.0280	0.0280	0.0280	0.0280	AID1912693
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	0.0218	0.0000	0.7340	10.0000	AID1189519; AID1357599; AID1491583; AID1578118; AID1824108; AID1913106; AID1913730; AID496759; AID626765; AID626766; AID626767; AID626769; AID626773; AID640398; AID648506; AID725591; AID727787
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Mus musculus (house mouse)	IC50 (µMol)	0.0086	0.0086	0.3362	0.5000	AID626778
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	GI50	0.0280	0.0280	0.0280	0.0280	AID1912694
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	IC50 (µMol)	0.0276	0.0002	0.5953	10.0000	AID1189520; AID1326858; AID1491584; AID1578119; AID1824109; AID1913107; AID496760; AID626772; AID626777; AID648507; AID725590; AID727786
Serine/threonine-protein kinase mTOR	Homo sapiens (human)	IC50 (µMol)	0.3633	0.0000	0.8575	10.0000	AID1177103; AID1321996; AID640397
Serine/threonine-protein kinase mTOR	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0450	0.0450	1.2725	2.5000	AID474309
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	GI50	0.0280	0.0280	0.0280	0.0280	AID1912696
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0369	0.0003	0.6607	10.0000	AID1189521; AID1424604; AID1491585; AID1578121; AID1824110; AID1913109; AID496761; AID626770; AID648508; AID725589; AID727785
Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0012	0.9137	7.0000	AID1321995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	EC50 (µMol)	0.0100	0.0080	0.0428	0.0930	AID1406827; AID1421732
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	EC50 (µMol)	0.0500	0.0400	0.0467	0.0500	AID1406820; AID1406823
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	EC50 (µMol)	0.0500	0.0240	0.2404	1.8000	AID1406820; AID1406823; AID1421725; AID1421728
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	EC50 (µMol)	0.0440	0.0150	0.0295	0.0440	AID1406825; AID1421730
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	EC50 (µMol)	0.0510	0.0510	0.0590	0.0670	AID1406826; AID1421731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Proteinase-activated receptor 1	Homo sapiens (human)	Imax	1.3750	0.2500	1.3750	2.5000	AID1326873; AID1326902
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	Imax	0.2500	0.2500	0.2500	0.2500	AID1326872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of epithelial tube formation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol biosynthetic process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
exocytosis	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
positive regulation of autophagy	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
vascular associated smooth muscle contraction	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
clathrin coat assembly	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
membrane organization	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
cell migration	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
biological_process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cellular response to starvation	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
autophagosome organization	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cell migration	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
connective tissue replacement involved in inflammatory response wound healing	Proteinase-activated receptor 1	Homo sapiens (human)
negative regulation of glomerular filtration	Proteinase-activated receptor 1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Proteinase-activated receptor 1	Homo sapiens (human)
inflammatory response	Proteinase-activated receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Proteinase-activated receptor 1	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Proteinase-activated receptor 1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Proteinase-activated receptor 1	Homo sapiens (human)
establishment of synaptic specificity at neuromuscular junction	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of cell population proliferation	Proteinase-activated receptor 1	Homo sapiens (human)
negative regulation of cell population proliferation	Proteinase-activated receptor 1	Homo sapiens (human)
response to wounding	Proteinase-activated receptor 1	Homo sapiens (human)
anatomical structure morphogenesis	Proteinase-activated receptor 1	Homo sapiens (human)
platelet activation	Proteinase-activated receptor 1	Homo sapiens (human)
regulation of blood coagulation	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of blood coagulation	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of cell migration	Proteinase-activated receptor 1	Homo sapiens (human)
response to lipopolysaccharide	Proteinase-activated receptor 1	Homo sapiens (human)
regulation of interleukin-1 beta production	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of interleukin-6 production	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of interleukin-8 production	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Proteinase-activated receptor 1	Homo sapiens (human)
dendritic cell homeostasis	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of MAPK cascade	Proteinase-activated receptor 1	Homo sapiens (human)
negative regulation of neuron apoptotic process	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of GTPase activity	Proteinase-activated receptor 1	Homo sapiens (human)
cell-cell junction maintenance	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of vasoconstriction	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of smooth muscle contraction	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Proteinase-activated receptor 1	Homo sapiens (human)
regulation of synaptic plasticity	Proteinase-activated receptor 1	Homo sapiens (human)
homeostasis of number of cells within a tissue	Proteinase-activated receptor 1	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of calcium ion transport	Proteinase-activated receptor 1	Homo sapiens (human)
regulation of sensory perception of pain	Proteinase-activated receptor 1	Homo sapiens (human)
platelet dense granule organization	Proteinase-activated receptor 1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Proteinase-activated receptor 1	Homo sapiens (human)
thrombin-activated receptor signaling pathway	Proteinase-activated receptor 1	Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	Proteinase-activated receptor 1	Homo sapiens (human)
negative regulation of renin secretion into blood stream	Proteinase-activated receptor 1	Homo sapiens (human)
intracellular glucose homeostasis	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of leukocyte migration	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
transcription by RNA polymerase II	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein import into nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
immune response	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytokine-mediated signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
osteoclast differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of RNA splicing	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
regulation of toll-like receptor 4 signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cellular response to UV	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
response to endoplasmic reticulum stress	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
interleukin-18-mediated signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
natural killer cell mediated cytotoxicity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of protein import into nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of apoptotic process	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of osteoclast differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of glucose import	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein stabilization	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of filopodium assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of stress fiber assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
growth hormone receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
myeloid leukocyte migration	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of focal adhesion disassembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein response	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
liver development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vasculature development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
glucose metabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phagocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle inactivity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of macroautophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
actin cytoskeleton organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of actin filament depolymerization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell costimulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of TOR signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle stretch	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of multicellular organism growth	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to L-leucine	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cellular respiration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of neuron apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
relaxation of cardiac muscle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
adipose tissue development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to glucose stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to hydrostatic pressure	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to dexamethasone	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle cell contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
energy homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of actin filament organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
autosome genomic imprinting	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to butyrate	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of protein localization to membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cell-matrix adhesion	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
response to ischemia	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular calcium ion homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
embryonic cleavage	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of MAPK cascade	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
angiogenesis involved in wound healing	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein destabilization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of macroautophagy	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of cell growth	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
T-helper 1 cell lineage commitment	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
heart morphogenesis	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
heart valve morphogenesis	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
energy reserve metabolic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
inflammatory response	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytoskeleton organization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
lysosome organization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
germ cell development	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
response to nutrient	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of cell size	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to starvation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
response to heat	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
post-embryonic development	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of autophagy	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of lamellipodium assembly	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of gene expression	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of myotube differentiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
neuronal action potential	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein catabolic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of cell growth	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of actin filament polymerization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
T cell costimulation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
ruffle organization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of myelination	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
response to nutrient levels	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to nutrient levels	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to nutrient	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
TOR signaling	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to insulin stimulus	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of actin cytoskeleton organization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
calcineurin-NFAT signaling cascade	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to amino acid starvation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
multicellular organism growth	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
TORC1 signaling	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of circadian rhythm	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
response to amino acid	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
anoikis	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of osteoclast differentiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of translation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of cell size	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of glycolytic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of translational initiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of lipid biosynthetic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
behavioral response to pain	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
rhythmic process	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
oligodendrocyte differentiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
voluntary musculoskeletal movement	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of stress fiber assembly	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of keratinocyte migration	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
nucleus localization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cardiac muscle cell development	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cardiac muscle contraction	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to methionine	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to amino acid stimulus	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to L-leucine	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to hypoxia	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to osmotic stress	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of membrane permeability	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of cellular response to heat	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of protein localization to nucleus	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of transcription of nucleolar large rRNA by RNA polymerase I	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of wound healing, spreading of epidermal cells	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of locomotor rhythm	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of cytoplasmic translational initiation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of lysosome organization	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
positive regulation of pentose-phosphate shunt	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cellular response to leucine starvation	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
regulation of autophagosome assembly	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
negative regulation of macroautophagy	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
dendritic cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of acute inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of triglyceride catabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
secretory granule localization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of MAP kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cellular response to cAMP	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
hepatocyte apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of calcium ion transmembrane transport	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein lipidation	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autophagy	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autophagosome assembly	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
protein targeting to lysosome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
regulation of autophagy	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
macroautophagy	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
regulation of macroautophagy	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
regulation of cytokinesis	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
protein localization to phagophore assembly site	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
cellular response to glucose starvation	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
positive regulation by host of viral genome replication	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
early endosome to late endosome transport	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
cell division	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autophagosome maturation	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autophagy of peroxisome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
endocytosis	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
clathrin binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
phosphatidylinositol binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
protein binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol binding	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
G-protein alpha-subunit binding	Proteinase-activated receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	Proteinase-activated receptor 1	Homo sapiens (human)
signaling receptor binding	Proteinase-activated receptor 1	Homo sapiens (human)
protein binding	Proteinase-activated receptor 1	Homo sapiens (human)
thrombin-activated receptor activity	Proteinase-activated receptor 1	Homo sapiens (human)
G-protein beta-subunit binding	Proteinase-activated receptor 1	Homo sapiens (human)
phosphotyrosine residue binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin-like growth factor receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
neurotrophin TRKA receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein phosphatase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulatory subunit binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
ErbB-3 class receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein heterodimerization activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
enzyme-substrate adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein kinase activator activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Mus musculus (house mouse)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
RNA polymerase III type 1 promoter sequence-specific DNA binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
RNA polymerase III type 2 promoter sequence-specific DNA binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
RNA polymerase III type 3 promoter sequence-specific DNA binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
TFIIIC-class transcription factor complex binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
ribosome binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
phosphoprotein binding	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
protein kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
identical protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ephrin receptor binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein kinase activity	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
protein binding	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
ATP binding	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
kinase activity	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
trans-Golgi network	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
clathrin-coated vesicle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
vesicle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
extracellular exosome	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
endoplasmic reticulum	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytosol	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
endocytic vesicle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	Proteinase-activated receptor 1	Homo sapiens (human)
extracellular region	Proteinase-activated receptor 1	Homo sapiens (human)
early endosome	Proteinase-activated receptor 1	Homo sapiens (human)
late endosome	Proteinase-activated receptor 1	Homo sapiens (human)
Golgi apparatus	Proteinase-activated receptor 1	Homo sapiens (human)
plasma membrane	Proteinase-activated receptor 1	Homo sapiens (human)
caveola	Proteinase-activated receptor 1	Homo sapiens (human)
cell surface	Proteinase-activated receptor 1	Homo sapiens (human)
platelet dense tubular network	Proteinase-activated receptor 1	Homo sapiens (human)
neuromuscular junction	Proteinase-activated receptor 1	Homo sapiens (human)
postsynaptic membrane	Proteinase-activated receptor 1	Homo sapiens (human)
nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cis-Golgi network	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cell-cell junction	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear endoplasmic reticulum membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
intercalated disc	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
lamellipodium	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Mus musculus (house mouse)
nucleus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleolus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
midbody	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
PML body	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
lysosomal membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
Golgi membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
mitochondrial outer membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
lysosome	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
lysosomal membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
endomembrane system	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
membrane	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
TORC1 complex	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
TORC2 complex	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
phagocytic vesicle	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
nuclear envelope	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase mTOR	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
late endosome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autophagosome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
cytosol	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
axoneme	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
membrane	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
midbody	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phagocytic vesicle membrane	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class III	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
autolysosome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
peroxisome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class III, type II	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
endosome	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
membrane	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phagophore assembly site	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class III, type I	Phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (226)

Assay ID	Title	Year	Journal	Article
AID1345786	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (Phosphatidylinositol kinases)	2006	Journal of the National Cancer Institute, Apr-19, Volume: 98, Issue:8	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
AID1345778	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (Phosphatidylinositol kinases)	2006	Journal of the National Cancer Institute, Apr-19, Volume: 98, Issue:8	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
AID1345748	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (Phosphatidylinositol kinases)	2006	Journal of the National Cancer Institute, Apr-19, Volume: 98, Issue:8	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1321995	Inhibition of human recombinant Vps34 using substrate PI incubated for 1 hr by Adapta kinase assay	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
AID474312	Antiproliferative activity against human LNCAP cells after 3 days by MTS assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
AID1331823	Antimigratory activity in human MDA-MB-231 cells assessed as decrease in cell adhesion at 0.25 uM after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis and anti-metastatic effects of pregn-17(20)-en-3-amine derivatives.
AID1406822	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID648501	Growth inhibition of human MKN28 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1578120	Competitive inhibition of PI3Kdelta (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
AID1421725	Inhibition of PI3Kalpha H1047R mutant (unknown origin) by HTRF assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID626764	Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1406826	Inhibition of PI3K-gamma (unknown origin) after 40 mins by Kinase-Glo assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID725591	Inhibition of PI3Kalpha (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
AID648499	Growth inhibition of human MKN1 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1421730	Inhibition of PI3Kbeta (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1189521	Inhibition of PI3K p110gamma (unknown origin)	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID648346	Growth inhibition of human SF295 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID727784	Inhibition of PI3K-delta (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID719910	Inhibition of PI3Kdelta	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
AID1421745	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 5 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 2.35%)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID719923	Selectivity ratio of IC50 for PI3Kgamma to IC50 for PI3Kdelta	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
AID640397	Inhibition of mTOR	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
AID626769	Inhibition of human His-tagged PI3K p110alpha H1047R mutant after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID626778	Inhibition of mouse recombinant PI3K p110alpha expressed in Sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1307781	Cytotoxic activity against human D54 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
AID1193976	Inhibition of PI3K in mouse lung fibroblast assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID648504	Growth inhibition of human DU145 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648365	Growth inhibition of human OVCAR5 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID496761	Inhibition of p110gamma	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
AID626773	Inhibition of human His-tagged PI3K p110alpha after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648351	Growth inhibition of human KM12 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648360	Growth inhibition of human DMS273 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648340	Growth inhibition of human BSY1 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1491585	Inhibition of recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system by TR-FRET assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID1824108	Inhibition of human PI3Kalpha by TR-FRET based Adapta assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
AID648369	Growth inhibition of human ACHN cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1578118	Competitive inhibition of PI3Kalpha (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
AID626777	Inhibition of human recombinant PI3K p110beta expressed in Sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1491586	Inhibition of recombinant human full length His-tagged PI3K p110delta/p85alpha expressed in baculovirus expression system coexpressing PIK3R1 by TR-FRET assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID753013	Toxicity in rag1-deficient mouse xenografted with human U87MG cells assessed as mortality at 40 mg/kg, ip qd after 14 days relative to control	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID727779	Cytotoxicity against PTEN-deficient human MDA-MB-468 cells assessed as inhibition of cell growth after 48 hrs by Cell Titer 96 assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID626772	Inhibition of human His-tagged PI3K p110beta after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648505	Growth inhibition of human PC3 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID752998	Antitumor activity against human U87MG cells xenografted in rag1-deficient mouse assessed as tumor growth inhibition at 40 mg/kg, ip qd measured after 14 days relative to control	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648339	Growth inhibition of human HBC4 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID727785	Inhibition of PI3K-gamma (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID474310	Inhibition of PI3K assessed as PIP3 level after 20 mins by HTRF assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
AID648508	Inhibition of recombinant PI3Kgamma HTRF assay	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1193977	Inhibition of MEK1 in mouse lung fibroblast assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID640398	Inhibition of PI3Kalpha	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
AID1326872	Inhibition of PI3Kbeta in human washed platelets assessed as suppression of ADP-induced integrin alpha2bbeta3 activation preincubated for 5 mins followed by ADP stimulation after 10 mins by OG-FNG-based FACS analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
AID1406823	Inhibition of recombinant full length PI3K p110alpha/p85alpha (unknown origin) expressed in baculovirus infected sf9 cells using PIP2 as substrate preincubated for 10 mins followed by ATP addition and measured after 45 mins by HTRF assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID496759	Inhibition of p110alpha	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
AID648359	Growth inhibition of human A549 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648343	Growth inhibition of human MDA-MB-231 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648507	Inhibition of recombinant PI3Kbeta HTRF assay	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1491588	Selectivity ratio of IC50 for recombinant human full length His-tagged PI3K p110gamma expressed in baculovirus expression system to IC50 for recombinant human full length His-tagged PI3K p110alpha/p85alpha expressed in baculovirus expression system	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID648364	Growth inhibition of human OVCAR4 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1578121	Competitive inhibition of PI3Kgamma (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
AID1321991	Inhibition of human recombinant PI3KC2alpha using substrate PI incubated for 1 hr by Adapta kinase assay	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
AID1326873	Inhibition of PAR1 in human washed platelets assessed as suppression of TRAP-induced integrin alpha2bbeta3 activation preincubated for 5 mins followed by TRAP stimulation after 10 mins by OG-FNG-based FACS analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
AID1824111	Inhibition of human PI3Kdelta by TR-FRET based Adapta assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
AID1177100	Inhibition of human PI3KCdelta by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID1824109	Inhibition of human PI3Kbeta by TR-FRET based Adapta assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
AID648500	Growth inhibition of human MKN7 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1578119	Competitive inhibition of PI3Kbeta (unknown origin)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
AID1406825	Inhibition of PI3K-beta (unknown origin) after 40 mins by Kinase-Glo assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID1189519	Inhibition of PI3K p110alpha (unknown origin)	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID626742	AUC (infinity) in CD1 mouse at 10 mg/kg, ip administered as single dose by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1421731	Inhibition of PI3Kgamma (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1357599	Inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate after 1 hr by Kinase-Glo luminescent kinase assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Phthalimide conjugations for the degradation of oncogenic PI3K.
AID626768	Toxicity in PTEN-deficient human U87MG cells xenografted Rag1-/- mouse assessed as body weight loss at 40 mg/kg, ip qd for 10 days	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648353	Growth inhibition of human HCT15 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID626763	Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblott	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1177094	Inhibition of human PI3KC2alpha by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID1189520	Inhibition of PI3K p110beta (unknown origin)	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID626767	Inhibition of human PI3K p110alpha helical domain E545K mutant after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID496762	Inhibition of p110delta	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
AID648368	Growth inhibition of human RXF631L cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID725590	Inhibition of PI3Kbeta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
AID640399	Selectivity ratio of IC50 for PI3Kaplha to IC50 for mTOR	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
AID1824110	Inhibition of human PI3Kgamma by TR-FRET based Adapta assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
AID648361	Growth inhibition of human DMS114 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID496760	Inhibition of p110beta	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
AID648355	Growth inhibition of human NCI-H23 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID725588	Inhibition of PI3Kdelta (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
AID719925	Selectivity ratio of IC50 for PI3Kbeta to IC50 for PI3Kdelta	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
AID648358	Growth inhibition of human NCI-H483 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1326858	Inhibition of PI3Kbeta (unknown origin) expressed in Escherichia coli-infected fall armyworm sf21 cells co-expressing p85 by kinase-glo luminescence assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
AID1177095	Inhibition of human PI3KC2beta by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID1307783	Cytotoxic activity against human D54 cells assessed as reduction in cell viability incubated for 48 hrs in presence of PD0325901 by alamar blue assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
AID1321996	Inhibition of human recombinant mTOR using substrate PI incubated for 1 hr by Adapta kinase assay	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
AID626770	Inhibition of human His-tagged PI3K p110gamma after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1421761	Induction of autophagy in human HCT116 cells assessed as accumulation of GFP/mRFP-tagged LC3 accumulation in cytoplasm after 12 hrs by laser scanning confocal microscopic analysis	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID648349	Growth inhibition of human SNB78 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID727787	Inhibition of PI3K-alpha (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID1326902	Inhibition of PAR1 in human washed platelets assessed as suppression of TRAP-induced platelet aggregation preincubated for 5 mins followed by TRAP stimulation after 10 mins by light transmission aggregometric analysis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
AID626771	Inhibition of human His-tagged PI3K p110delta after 2 hrs by HTRF assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1421727	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID626766	Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Ser473 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648357	Growth inhibition of human NCI-H522 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648345	Growth inhibition of human SF268 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648503	Growth inhibition of human MKN74 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1424603	Inhibition of PI3K in human A549 cell lysates assessed as remaining enzyme activity at 1 uM pre-incubated for 5 mins before [gamma-32P]ATP addition and further incubated for 20 mins by TLC and autoradiography relative to untreated control	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	1,3,5-Triazines: A promising scaffold for anticancer drugs development.
AID1193964	Inhibition of PI3K in human PANC1 cells assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1421760	Induction of autophagy in human HCT116 cells assessed as autophagic vacuole formation at 5 uM after 6 hrs by MDC staining based fluorescence microscopic analysis	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1421732	Inhibition of PI3Kdelta (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID626745	Cmax in CD1 mouse at 10 mg/kg, ip administered as single dose by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID626781	Aqueous solubility of the compound in DMSO after 15 mins by HPLC analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1406821	Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID648348	Growth inhibition of human SNB75 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1491583	Inhibition of recombinant human full length His-tagged PI3K p110alpha/p85alpha expressed in baculovirus expression system coexpressing PIK3R1 by TR-FRET assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID1193965	Inhibition of MEK1 in human PANC1 cells assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID648498	Growth inhibition of human St-4 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID626741	Half life in CD1 mouse at 10 mg/kg, ip administered as single dose by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1421726	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID648350	Growth inhibition of human HCC2998 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1421728	Inhibition of wild type PI3Kalpha (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID474309	Inhibition of rat brain mTOR assessed as p70S6K-GST protein phosphorylation after 30 mins by ELISA	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
AID1177103	Inhibition of human mTOR by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID626743	Tmax in CD1 mouse at 10 mg/kg, ip administered as single dose by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID626739	Antitumor activity in PTEN-deficient human U87MG xenografted in Rag1-/- mouse assessed as inhibition of tumor growth at 40 mg/kg, ip qd for 10 days measured after 10 days (Rvb = 18.5 +/- 3.4%)	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID648347	Growth inhibition of human SF539 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1421744	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 5 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 4.07%)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1177096	Inhibition of human PI3KC2gamma by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID648506	Inhibition of recombinant PI3Kalpha by HTRF assay	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID727786	Inhibition of PI3K-beta (unknown origin) assessed as decrease in ATP consumption using phosphatidylinositol bisphosphate and 10 uM ATP as substrate measured after 60 mins by luminescence assay	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID1491587	Selectivity ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for recombinant human full length His-tagged PI3K p110alpha/p85alpha expressed in baculovirus expression system	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID1707081	Antiproliferative activity against human HT-29 cells incubated for 3 days by WST8 assay
AID648341	Growth inhibition of human HBC5 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1491584	Inhibition of PI3Kbeta (unknown origin) by TR-FRET assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID719924	Selectivity ratio of IC50 for PI3Kalpha to IC50 for PI3Kdelta	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
AID1189522	Inhibition of PI3K p110delta (unknown origin)	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID648342	Growth inhibition of human MCF7 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1193970	Inhibition of PI3K in human A549 cells assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1424604	Inhibition of PI3K p110gamma/p85alpha (unknown origin) assessed as reduction in PIP2 to PIP3 conversion by HTRF assay	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	1,3,5-Triazines: A promising scaffold for anticancer drugs development.
AID648344	Growth inhibition of human U251 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648354	Growth inhibition of human HCT116 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648367	Growth inhibition of human SKOV3 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID626775	Antiproliferative activity against human NZB5 cells expressing wild type p110alpha assessed as incorporation of [3H]thymidine after 5 days	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID725589	Inhibition of PI3Kgamma (unknown origin) expressed in SF21 cells using phosphatidylinositol as substrate after 60 mins by Kinase-Glo assay	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
AID1491590	Selectivity ratio of IC50 for recombinant human full length His-tagged PI3K p110delta/p85alpha expressed in baculovirus expression system to IC50 for recombinant human full length His-tagged PI3K p110delta/p85alpha expressed in baculovirus expression syst	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID1307780	Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
AID648509	Inhibition of recombinant PI3Kdelta HTRF assay	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648356	Growth inhibition of human NCI-H226 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648352	Growth inhibition of human HT-29 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1177098	Inhibition of human class 3 PI3K by non-radiometric ADP-Glo assay	2015	ACS medicinal chemistry letters, Jan-08, Volume: 6, Issue:1	Class II but Not Second Class-Prospects for the Development of Class II PI3K Inhibitors.
AID753012	Toxicity in rag1-deficient mouse xenografted with human U87MG cells assessed as body weight loss at 40 mg/kg, ip qd after 14 days relative to control	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1491589	Selectivity ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for recombinant human full length His-tagged PI3K p110delta/p85alpha expressed in baculovirus expression system	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
AID648502	Growth inhibition of human MKN45 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1321992	Inhibition of human recombinant PI3KC2beta using substrate PI incubated for 1 hr by Adapta kinase assay	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
AID1421746	Induction of apoptosis in human HCT116 cells assessed as viable cells at 5 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 93%)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1321994	Inhibition of his-tagged human recombinant PIK3CD/PIK3R1 using substrate PI incubated for 1 hr by Adapta kinase assay	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Class II Phosphoinositide 3-Kinases as Novel Drug Targets.
AID648362	Growth inhibition of human LOXIMVI cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID648366	Growth inhibition of human OVCAR8 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID626776	Inhibition of bovine recombinant PI3K p110delta expressed in Sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID474311	Selectivity ratio of IC50 for PI3K to IC50 for rat brain mTOR	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
AID1406828	Inhibition of mTORC1 (unknown origin)	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID1421733	Inhibition of mTORC1 (unknown origin) after 40 mins by kinase-Glo reagent based luminescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID648363	Growth inhibition of human OVCAR3 cells	2012	Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
AID1421747	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 5 uM after 24 hrs by Annexin V-FITC/PI staining based flow cytometry (Rvb = 0.39%)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
AID1406827	Inhibition of PI3K-delta (unknown origin) after 40 mins by Kinase-Glo assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID1406820	Inhibition of recombinant full length PI3K p85alpha/p110alpha H1047R mutant (unknown origin) expressed in baculovirus infected sf9 cells using PIP2 as substrate preincubated for 10 mins followed by ATP addition and measured after 45 mins by HTRF assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
AID626774	Antiproliferative activity against human NZOV9 cells expressing p110alpha kinase Y1021C mutant assessed as incorporation of [3H]thymidine after 5 days	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID626765	Inhibition of PIK3CA-mediated cell signaling in PTEN-deficient human U87MG cells assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
AID1193971	Inhibition of MEK1 in human A549 cells assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID727783	Ratio of IC50 for PI3K-beta (unknown origin) to IC50 for PI3K-delta (unknown origin)	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159587	Biochemical screen of P. falciparum PK7	2016	PloS one, , Volume: 11, Issue:3	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589	Biochemical screen of P. falciparum MAPK2	2016	PloS one, , Volume: 11, Issue:3	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586	Biochemical screen of P. falciparum PK6	2016	PloS one, , Volume: 11, Issue:3	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588	Biochemical screen of P. falciparum CDPK4	2016	PloS one, , Volume: 11, Issue:3	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585	Biochemical screen of P. falciparum CDPK1	2016	PloS one, , Volume: 11, Issue:3	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (6.38)	29.6817
2010's	73 (77.66)	24.3611
2020's	15 (15.96)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	7 (7.45%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	87 (92.55%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.13	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
berberine [no description available]	3.17	1	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	3.25	1	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.13	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	4.78	9	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
myoseverin myoseverin: a micotubule-binding molecule with cellular effects; structure in first source	3.25	1
temozolomide [no description available]	7.41	1	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.13	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
tolazoline hydrochloride [no description available]	2.13	1	benzenes
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.17	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.51	2	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.17	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.07	1	xanthene
morpholine [no description available]	7.41	1	morpholines; saturated organic heteromonocyclic parent	NMR chemical shift reference compound
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.49	2	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.78	3	indazole
thiazoles [no description available]	2.15	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.1	1	diazine; pyrazines	Daphnia magna metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.13	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.55	2
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2.17	1	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
2-fluoroadenine 2-fluoroadenine : An organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine.	2.13	1	organofluorine compound; purines	antineoplastic agent
hydroxychloroquine sulfate [no description available]	2.13	1
deoxycytidine [no description available]	2.07	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
c 137 C 137: RN given refers to parent cpd	2.13	1
imidocarb Imidocarb: One of ANTIPROTOZOAL AGENTS used especially against BABESIA in livestock. Toxicity has been reported.	2.13	1	ureas	antiprotozoal drug
metoprine metoprine: histamine methyltransferase antagonist	2.13	1
parbendazole parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd	2.13	1	benzimidazoles; carbamate ester
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.13	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
thymolphthalein Thymolphthalein: Used as a pH indicator and as a reagent for blood after decolorizing the alkaline solution by boiling with zinc dust.	2.13	1	terpene lactone
triazinate triazinate: structure	2.13	1
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	2.13	1
antineoplaston a10 antineoplaston A10: peptide analogue isolated from human urine	2.6	1
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	7.07	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
flucofuron flucofuron: structure given in first source. flucofuron : A member of the class of phenylureas that is urea in which each nitrogen is substituted by a 4-chloro-3-(trifluoromethyl)phenyl group.	2.13	1	(trifluoromethyl)benzenes; monochlorobenzenes; organochlorine pesticide; organofluorine pesticide; phenylureas	epitope
epiroprim epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source	2.13	1
2,2',2''-terpyridine 2,2',2''-terpyridine: RN given refers to parent cpd. 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings.	2.13	1	terpyridines	chelator
chaparrinone chaparrinone: quassinoid which inhibits protein sunthesis & DNA synthesis in cells; structure in first source	2.13	1	triterpenoid
thianthrene 5-oxide thianthrene 5-oxide: used as a probe of the electrophilicity of hemoprotein oxidizing species; structure given in first source	2.13	1
tryptanthrine tryptanthrine: minor constituent of traditional Chinese medicine qing dai	2.13	1	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound
remikiren [no description available]	2.13	1	azaspiro compound; oxaspiro compound; steroid
gallein gallein: do not confuse with gallin; structure. gallein : A xanthene dye that is fluoran carrying four hydroxy substituents at positions 3', 4', 5' and 6'.	2.07	1	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorochrome; G-protein-coupled receptor antagonist; histological dye
ro 22-3581 [no description available]	2.13	1
chloroquine diphosphate [no description available]	2.13	1
ethylhydrocupreine ethylhydrocupreine: structure; RN given refers to parent cpd. optochin : A cinchona alkaloid consisting of 10,11-dihydrocinchonan bearing hydroxy and ethoxy substituents at positions 9 and 6' respectively.	2.13	1	aromatic ether; cinchona alkaloid	EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
cinchonine [no description available]	2.13	1	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
wr 158122 WR 158122: structure	2.13	1
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline 3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline: structure given in first source	2.13	1
cinchonidine cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer. cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.	2.13	1	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.54	2	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.49	2	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate [no description available]	2.13	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
my 12-62c MY 12-62c: from Pseudomonas methanica KY4634. 2-heptyl-4-quinolone : A quinolone consisting of quinolin-4(1H)-one carrying a heptyl substituent at position 2.. 2-heptyl-4-hydroxyquinoline : A monohydroxyquinoline that is 4-hydroxyquinoline bearing an additional heptyl substituent at position 2.	2.13	1	monohydroxyquinoline; quinolone	antibacterial agent; iron chelator; metabolite; signalling molecule
erlotinib hydrochloride [no description available]	2.79	3	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	2.13	1	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
wortmannin [no description available]	3.55	2	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
bortezomib [no description available]	2.1	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.13	1	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
pseudolycorine pseudolycorine: alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb; structure in first source	2.13	1	phenanthridines
jp-1302 [no description available]	2.13	1
TCMDC-138263 [no description available]	2.13	1	harmala alkaloid
s 1033 [no description available]	2.15	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source	2.13	1	benzimidazoles
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor	2.13	1
2-[4-chloro-5-(cyclopentylsulfamoyl)-2-methylphenoxy]-N-cyclohexylacetamide [no description available]	2.13	1	sulfonamide
stk295900 [no description available]	2.13	1
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole [no description available]	2.13	1	benzimidazoles
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea [no description available]	2.13	1	pyrazoles; ring assembly
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	2.13	1	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
azoxystrobin azoxystrobin: a methoxyacrylate analog; a strobilurin fungicide; structure given in first source. azoxystrobin : An aryloxypyrimidine having a 4,6-diphenoxypyrimidine skeleton in which one of the phenyl rings is cyano-substituted at C-2 and the other carries a 2-methoxy-1-(methoxycarbonyl)vinyl substituent, also at C-2. An inhibitor of mitochondrial respiration by blocking electron transfer between cytochromes b and c1, it is used widely as a fungicide in agriculture.	2.13	1	aryloxypyrimidine; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; methyl ester; nitrile	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; quinone outside inhibitor; xenobiotic
trequinsin hydrochloride [no description available]	2.13	1
abbott 41988 Abbott 41988: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure	2.13	1
N-[4-(1H-benzimidazol-2-yl)phenyl]-4-ethoxy-3-nitrobenzamide [no description available]	2.13	1	benzimidazoles
2-[2-methoxyethyl-(1-oxo-2-thiophen-2-ylethyl)amino]-N-[(4-methoxyphenyl)methyl]-2-(4-propan-2-ylphenyl)acetamide [no description available]	2.13	1	monoterpenoid
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.13	1
7-chloro-N-(phenylmethyl)-4-quinolinamine [no description available]	2.13	1	aminoquinoline
5-[(5-bromo-2-hydroxyphenyl)-oxomethyl]-1-cyclohexyl-2-oxo-3-pyridinecarbonitrile [no description available]	2.13	1	aromatic ketone
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.13	1	benzamides
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.07	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
daphnetin [no description available]	2.13	1	hydroxycoumarin
hispidulin hispidulin : A monomethoxyflavone that is scutellarein methylated at position 6.	2.13	1	monomethoxyflavone; trihydroxyflavone	anti-inflammatory agent; anticonvulsant; antineoplastic agent; antioxidant; apoptosis inducer; plant metabolite
morusin morusin: from Morus root bark; structure given in first source. morusin : An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8.	2.13	1	extended flavonoid; trihydroxyflavone	antineoplastic agent; plant metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.33	6	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
as 605240 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione: a PI3Kgamma inhibitor; structure in first source. (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione : A quinoxaline derivative that is quinoxaline in which the hydrogen at position 6 is replaced by a (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl group. It is a potent inhibitor of the PI3Kgamma, with an IC50 of 8 nM and inhibits the progression of joint inflammation and damage in both lymphocyte-independent and dependent mouse models of rheumatoid arthritis.	3.61	2	quinoxaline derivative; thiazolidinediones	anti-inflammatory agent; antirheumatic drug; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
olvanil [no description available]	2.13	1	methoxybenzenes; phenols
pd 166285 [no description available]	2.13	1
pd-173952 [no description available]	2.13	1
10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one [no description available]	2.13	1	pyridochromene
mkt 077 MKT 077: structure given in first source	3.17	1
bvt.948 [no description available]	2.13	1
edatrexate edatrexate: structure given in first source	2.13	1	glutamic acid derivative
pq 401 PQ 401: an IGF receptor type I antagonist; structure in first source	2.13	1	quinolines
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.82	3	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
ic 86621 1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone: a DNA-dependent protein kinase inhibitor	2.11	1	aromatic ketone
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.11	1	organic heterotricyclic compound; organooxygen compound
nik 12192 4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzamide: structure in first source	2.13	1
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	4.29	5	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
3,5-bis(2-fluorobenzylidene)piperidin-4-one 3,5-bis(2-fluorobenzylidene)piperidin-4-one: an antineoplastic agent; structure in first source	2.17	1
PI3-Kinase alpha Inhibitor 2 [no description available]	2.11	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
tgx 221 TGX 221: a platelet aggregation inhibitor	2.81	3	pyridopyrimidine
ic 87114 IC 87114: structure in first source	3.57	2	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zm 447439 ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.	2.13	1	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor
tg100-115 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source	3.17	1	pteridines
pha 665752 [no description available]	2.13	1	dichlorobenzene; enamide; indolones; N-acylpyrrolidine; pyrrolecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide	antineoplastic agent; c-Met tyrosine kinase inhibitor
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	2.11	1	dibenzothiophenes
5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione: a PI3Kgamma inhibitor; structure in first source	3.17	1
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	4.98	6	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
as 252424 5-(5-(4-fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione: a PI3K gamma inhibitor; structure in first source	3.39	2
chir-265 [no description available]	2.51	2	aromatic ether
trametinib [no description available]	2.13	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
brl 15572 BRL 15572: specific for h5-HT(1D) receptors; structure in first source. 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride : A hydrochloride that is the monohydrochloride salt of 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.	2.13	1	hydrochloride	prodrug; serotonergic antagonist
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	5.48	11	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
ku 60019 [no description available]	2.11	1
amodiaquine hydrochloride [no description available]	2.13	1
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone [no description available]	3.31	1	pyrazolopyridine
oligonucleotides [no description available]	2.15	1
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	3.64	2	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ro5126766 RO5126766: a dual MEK/RAF kinase inhibitor. CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3.	2.11	1	aryloxypyrimidine; coumarins; organofluorine compound; pyridines; sulfamides	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.08	1	sulfonamide
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	5.55	6	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
puromycin dihydrochloride [no description available]	2.13	1
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.17	1	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	7.17	1	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
incb-018424 [no description available]	2.08	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.15	1	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
plx4032 [no description available]	2.31	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
kin-193 [no description available]	3.25	1	pyridopyrimidine
pki 402 PKI 402: also inhibits mammalian target of rapamycin; structure in first source	2.11	1
pki 587 gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source	2.11	1
au-1 [no description available]	2.13	1
vs-5584 VS-5584: a highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer	2.11	1
gsk2269557 Nemiralisib: PI3K delta - selective inhibitor	3.17	1
kp372-1 KP372-1: mixture of two isomers present in equal amounts; Akt kinase inhibitor; structure in first source	2.07	1
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.13	1	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ipi-145 [no description available]	2.57	2	isoquinolines
gdc-0032 [no description available]	2.15	1
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.11	1	benzenes; hydroxycoumarin; methyl ketone
sar245408 [no description available]	4.19	2
byl719 [no description available]	3.65	2	proline derivative
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.13	1
sar405 SAR405: a Vps34 inhibitor with antineoplastic activity; structure in first source	3.25	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.13	1
icg 001 ICG 001: PRI-724 is an enantiomer of ICG-001; binds to cAMP response element-binding protein; structure in first source	2.25	1
sb-590885 (Z)-SB-590885 : An N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine in which the oxime group has Z configuration.. (E)-SB-590885 : An N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine in which the oxime group has E configuration.	2.11	1	N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea [no description available]	2.13	1	quinazolines
1843u89 1843U89: structure given in first source; a folate analog	2.13	1
hesperadin [no description available]	2.13	1
cb 3717 [no description available]	2.13	1	N-acyl-L-glutamic acid
bay 80-6946 copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.	3.68	2
cb 3705 CB 3705: inhibitor of dihydrofolate reductase & thymidylate synthetase	2.13	1
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.84	3

Condition	Indicated	Relationship Strength	Studies
B16 Melanoma [description not available]	0	3.66	3
Benign Neoplasms [description not available]	0	5.74	10
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	7.74	10
Autoimmune Disease [description not available]	0	2.99	1
Innate Inflammatory Response [description not available]	0	3.71	3
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	2.99	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	3.71	3
Plasmodium falciparum Malaria [description not available]	0	2.13	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.13	1
Metastase [description not available]	0	2.51	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.51	2
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	0	3.06	1
Cancer of Liver [description not available]	0	2.61	2
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.61	2
Congenital Zika Syndrome [description not available]	0	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.64	8
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1
Agnogenic Myeloid Metaplasia [description not available]	0	2.41	1
Primary Myelofibrosis A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.	0	2.41	1
Osteogenic Sarcoma [description not available]	0	2.31	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	7.31	1
Benign Neoplasms, Brain [description not available]	0	2.41	1
Astrocytoma, Grade IV [description not available]	0	2.58	2
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.41	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	2.58	2
Acute Lymphoid Leukemia [description not available]	0	2.61	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	0	2.61	2
Hepatocellular Carcinoma [description not available]	0	2.25	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.25	1
Malignant Melanoma [description not available]	0	2.31	1
Cancer of Skin [description not available]	0	2.31	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.31	1
Skin Neoplasms Tumors or cancer of the SKIN.	0	2.31	1
Acute Myelogenous Leukemia [description not available]	0	2.15	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.15	1
Granulocytic Leukemia, Chronic [description not available]	0	2.54	2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.54	2
Cancer of the Thyroid [description not available]	0	2.81	3
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	0	2.81	3
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	0	2.54	2
Acute Autoimmune Neuropathy [description not available]	0	2.17	1
Clinically Isolated CNS Demyelinating Syndrome [description not available]	0	2.17	1
Allergic Neuritis, Experimental [description not available]	0	2.17	1
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	0	2.17	1
Guillain-Barre Syndrome An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)	0	2.17	1
Bone Cancer [description not available]	0	2.21	1
Angiogenesis, Pathologic [description not available]	0	2.78	3
Cancer of Prostate [description not available]	0	2.8	3
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.21	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.8	3
Invasiveness, Neoplasm [description not available]	0	2.08	1
Cancer of Ovary [description not available]	0	2.08	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.08	1
Hematologic Malignancies [description not available]	0	2.08	1
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	0	2.08	1
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	2.08	1
Allergic Encephalomyelitis [description not available]	0	2.1	1
Carcinoma, Non-Small Cell Lung [description not available]	0	2.11	1
Cancer of Lung [description not available]	0	2.11	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.11	1
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.11	1
Breast Cancer [description not available]	0	7.5	2
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.5	2
Pulmonary Arterial Remodeling [description not available]	0	2.13	1
Asthma, Bronchial [description not available]	0	2.13	1
Allergic Reaction [description not available]	0	2.13	1
Angiitis [description not available]	0	2.13	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	2.13	1
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	2.13	1
Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.	0	2.13	1
Anterior Cerebral Circulation Infarction [description not available]	0	2.13	1
Cerebral Ischemia [description not available]	0	7.13	1
Nervous System Disorders [description not available]	0	2.13	1
Injury, Ischemia-Reperfusion [description not available]	0	2.13	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.13	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	0	2.13	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	7.13	1
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	0	2.13	1
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	0	2.13	1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	0	2.13	1
Cancer of Kidney [description not available]	0	2.05	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.05	1
Adjuvant Arthritis [description not available]	0	2.47	2
Bone Loss, Osteoclastic [description not available]	0	2.05	1
Experimental Neoplasms [description not available]	0	3.39	2
Adenocarcinoma, Basal Cell [description not available]	0	2.07	1
Cancer of Pancreas [description not available]	0	2.07	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	7.07	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.07	1
Cancer of Cervix [description not available]	0	2.07	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.07	1
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	0	2.99	1
Cancer of Colon [description not available]	0	2.99	1
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.99	1
Rheumatoid Arthritis [description not available]	0	3.39	2
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	3.39	2
Canine Diseases [description not available]	0	2.07	1
Colorectal Cancer [description not available]	0	2.07	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	2.07	1

zstk474

Description

Cross-References

Synonyms (60)

Research Excerpts

Overview

Actions

Treatment

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (35)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (319)

Molecular Functions (58)

Ceullar Components (64)

Bioassays (226)

Research

Studies (94)

Market Indicators

Research Demand Index: 25.47

Study Types

zstk474

Description

Cross-References

Synonyms (60)

Research Excerpts

Overview

Actions

Treatment

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (35)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (319)

Molecular Functions (58)

Ceullar Components (64)

Bioassays (226)

Research

Studies (94)

Market Indicators

Research Demand Index: 25.47

Study Types

Related Drugs (151)

Related Conditions (99)